FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

OMB APPROVAL OMB Number: Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

E AMANI	,	Middle	:)			2. Issuer Name and Ticker or Trading Symbol ICU MEDICAL INC/DE [ICUI]								ck all app Direc	ctor			Owner	
E CA		(First) (Middle) LLE AMANECER				3. Date of Earliest Transaction (Month/Day/Year) 07/05/2018								Offic belov	er (give title w)	e	Othe belo	er (specify w)	
(Sta				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Tabl	e I -	Non-Deriv	ative	Seci	uritie	s Ac	quir	ed, C	Disposed (of, or I	Benefic	ially	/ Owne	ed				
Da		Date	Execution (Year)		ion Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Beneficially Owned Following		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) or (D)	Price		Transac	tion(s)			(Instr. 4)		
Common Stock 07/05/201			18	8			S ⁽¹⁾		947	D	\$287.5	9 ⁽²⁾	372	2,497		D			
ommon Stock 07/05/20.		18	8			S ⁽¹⁾		4,817	D	\$288.6	i7 ⁽³⁾ 3€		7,680		D				
mon Stock 07/05/203		18	8			S ⁽¹⁾		3,323	D	\$289.5	53 ⁽⁴⁾ 36		364,357		D				
ock			07/05/20	18				S ⁽¹⁾		1,709	D	\$290.4	7 ⁽⁵⁾	362,648		D			
Common Stock												986,843		B I		by Partnership			
	Та	ble I												Owned					
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			piration Date onth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number		t		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)			
CLEMENTE (City) (State) (Zip) Table I - Non- 1. Title of Security (Instr. 3) Common Stock Common Stock Common Stock Common Stock Table II - Do (e 1. Title of Derivative Security (Instr. 3) Table II - Do (e 3. Transaction Date (Month/Day/Year) Frice of Derivative Price of De		Table I - Non-Derivative (Instr. 3) 2. Transaction Date (Month/Day/form) ck 07/05/20 ck 07/05/20 ck 07/05/20 ck 07/05/20 ck 07/05/20 ck 3. Transaction Date (e.g., pinch/Day/form) ce of ce of rivative (Month/Day/Year)	Table I - Non-Derivative (Month/Day/Year) Ck	Table I - Non-Derivative Security (Instr. 3) 2. Transaction Date (Month/Day/Year) ck 07/05/2018 ck 07/05/	Table I - Non-Derivative Securities 2. Transaction Date (Month/Day/Year) ck 07/05/2018 ck	Table I - Non-Derivative Securities Activity (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Roginal Date (Month/Day/Year) 2. Transaction Date (Roginal Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Table I - Non-Derivative Securities Acquire (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Date (E.g., puts, calls, warrants, opt 4. Transaction Code (Instr. By) 4. Transaction Date (Month/Day/Year) 5. Number of Transaction Code (Instr. By) 6. Date (Month/Day/Year) 8. Date Date 1. Date (Month/Day/Year) 1. Date Date 1. Date 2. Date 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Transaction Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 2. Date 3. Transaction Date (Month/Day/Year) 4. Transaction Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 4. Date 5. Date 5. Date 6. Date 6. Date 6. Date 6. Date 7. Date 8. Date	Table I - Non-Derivative Securities Acquired, Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (if any (Month/Day/Year) 2. Transaction Date (if any (Month/Day/Year) 2. Transaction Date (If any (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Transaction Date (Month/Day/Year) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Date (Month/Day/Year) Date (Month/Day/Year	Table I - Non-Derivative Securities Acquired, Disposed of Pate (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 2A. Deemed Execution Date (Instr. 8) 3. Transaction Date (Policy of Pate 1) 3. Transaction Date (Month/Day/Year) 4. Securities Acquired (Month/Day/Year) 4. Securities Acquired (Instr. 8) 5. Instrument (Month/Day/Year) 5. Date Exercisable and Expiration Date (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 5. Date Exercisable and Expiration Date (Month/Da	Table I - Non-Derivative Securities Acquired, Disposed of, or Execution Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired Disposed Of (D) (Instr. 6) Code V Amount (A) or (D) Ck O7/05/2018 S(1) 4,817 D Ck O7/05/2018 S(1) 3,323 D Ck O7/05/2018 S(1) 3,323 D Ck O7/05/2018 S(1) 1,709 D O7/05/2018 O7/0	Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic Plate (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Date (Instr. 18) 5. Number (Barcuities Acquired (A) or Date (Barcuities Acquired (Ba	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) Code V Amount (A) or (D) Price (B) Code V Amount (B) or (D) Price (Ck 07/05/2018 S(1) 947 D \$288.67(3) S(1) 3,323 D \$288.67(3) S(1) 3,323 D \$289.53(4) S(1) 3,323 D \$289.53(4) S(1) 1,709 D \$290.47(5) S(1) S(1)	Calcab C	Carrity (Instr. 3) 2.A. Deemed Execution Date (Month/Day/Year) 2.A. Deemed Execution Date (P. Date Exercisable and Expiration Date (Month/Day/Year) 2.A. Deemed Execution Date (A. Securities Acquired (A.) or Date (Month/Day/Year) 2.A. Deamed Execution Date (A. Securities Acquired (A.) or Date (Month/Day/Year) 2.A. Deemed Execution Date (A. Securities Acquired (A.) or Date (Month/Day/Year) 2.A. Deemed Execution Date (A. Securities Acquired (A.) or Date (Month/Day/Year) 3.A. Deemed Execution Date (A. Gruired (A.) or Date (Month/Day/Year) 3.A. Deemed Execution Date (A. Gruired (A.) or Date (Month/Day/Year) 3.A. Deemed Execution Date (A. Gruired (A.) or Date (Month/Day/Year) 3.A. Deemed Execution Date (A. Gruired (A.) or Date (Month/Day/Year) 3.A. Deemed Execution Date (A. Gruired (A.) or Date (Month/Day/Year) 3.A. Deemed Execution Date (A. Gruired (A.) or Date (Month/Day/Year) 3.A. Deemed Expiration Date (Month/Day/Year) 3.A. Deemed E	Calcal C	Carrity (Instr. 3) 2. Transaction Date (Month/Day/Year) Month/Day/Year) Mo			

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.
- 2. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$287.05 to 288.05, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 3. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$288.10 to 289.10, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 4. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$289.15 to 290.15, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 5. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$290.20 to 291.10, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

By: Alejandro Parras,

Attorney-In-Fact For: George

07/09/2018

A. Lopez, M.D.

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.